source
- FDA says it will maintain Makary’s focus on clinical trials, rare diseases and China despite leadership exitsThe Food and Drug Administration announced that, even after the recent resignations of Commissioner Marty Makary and the heads of its drug and biologics centers, it will keep pursuing the policy ag…
- Takeda releases additional Phase 3 data to bolster its orexin program amid new competitionTakeda announced new results from its two Phase 3 trials of an orexin‑targeting therapy. The data are intended to demonstrate the drug’s efficacy and safety, reinforcing Takeda’s claim of market‑l…